- The Consumer Technology Association (CTA) awards Abbott
multiple CES 2023 Innovation Awards for industry-leading health
- Abbott's Aveir™ single-chamber (VR) leadless pacemaker,
Proclaim™ Plus SCS system, Alinity® m Monkeypox PCR test
- Other recent Abbott innovation honors include Abbott's
FreeStyle Libre® technology named the best medical
technology in the last 50 years by the Galien Foundation
PARK, Ill., Nov. 17,
2022 /PRNewswire/ -- Abbott (NYSE: ABT) has been
recognized by the Consumer Technology Association (CTA) with three
CES 2023 Innovation Awards for its life-changing technologies that
are advancing the health tech industry and improving the lives of
people worldwide. The CTA is the organization behind the Consumer
Electronics Show (CES), the most influential technology event in
Ahead of the CES 2023 event, three of Abbott's industry-leading
tech advancements won CES 2023 Innovation Awards, all within the
Digital Health award category:
- Aveir VR Leadless Pacemaker – The world's only
leadless pacemaker with a unique mapping capability to assess
correct positioning prior to placement and designed to be
completely retrievable. The system was developed by Abbott to treat
patients with slow heart rhythms and eliminates wires used to
deliver therapy in traditional pacemakers.
- Proclaim Plus SCS System – Abbott's latest advancement
in neurostimulation therapy to treat chronic pain using low doses
of targeted BurstDR™ stimulation that can be adjusted as a person's
therapeutic needs evolve across up to six areas of the body, which
is more pain sites in the body than ever before.
- Alinity m Monkeypox PCR test1 – A
first of its kind, Abbott received FDA Emergency Use Authorization
of its PCR test for detecting the monkeypox virus.
The CES Innovation Awards program is an annual competition
honoring outstanding design and engineering in consumer technology
products. The program recognizes the year's most innovative
products in a multitude of consumer technology product categories
and distinguishes the highest-rated in each.
Last year, Abbott became the first-ever healthcare company to
keynote CES, and the company has received nine CES Innovation
Awards in the past two years.
Other Abbott products previously honored with CES Innovation
Awards include FreeStyle Libre 32, the world's smallest,
thinnest3 and most accurate4 14-day glucose
sensor and a CES 2022 Best of Innovation Award winner;
BinaxNOW™5, the #1 COVID-19 self test in the U.S.; and
the UltreonTM 1.0 intravascular imaging and coronary
physiology software platform, which helps guide and optimize
stenting decisions, combining optical coherence tomography with
In addition to the CES 2023 awards, Abbott also was recently
recognized with other top honors for its healthcare technology
including its revolutionary FreeStyle Libre technology being named
the best medical technology in the last 50 years by the Galien
Foundation. The FreeStyle Libre portfolio has transformed the lives
of approximately 4.5 million people6 living with
Abbott is a global healthcare leader that helps people live more
fully at all stages of life. Our portfolio of life-changing
technologies spans the spectrum of healthcare, with leading
businesses and products in diagnostics, medical devices,
nutritionals and branded generic medicines. Our 113,000 colleagues
serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at
www.linkedin.com/company/abbott-/, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews.
1 This product has not been FDA cleared or approved,
but has been authorized for emergency use by FDA under an EUA for
use by the authorized laboratories; This product has been
authorized only for the detection of nucleic acid from monkeypox
virus, not for any other viruses or pathogens; The emergency use of
this product is only authorized for the duration of the declaration
that circumstances exist justifying the authorization of emergency
use of in vitro diagnostics for detection and/or diagnosis of
infection with the monkeypox virus, including in vitro diagnostics
that detect and/or diagnose infection with non-variola
Orthopoxvirus, under Section 564(b)(1) of the Federal Food, Drug,
and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the
declaration is terminated or authorization is revoked sooner.
2 Indications and Important Safety Information:
FreeStyle Libre 3 system: Failure to use the FreeStyle Libre 3
system as instructed in labeling may result in missing a severe low
or high glucose event and/or making a treatment decision, resulting
in injury. If glucose alarms and readings do not match symptoms or
expectations, use a fingerstick value from a blood glucose meter
for treatment decisions. Seek medical attention when appropriate or
contact Abbott at 855-632-8658 or FreeStyleLibre.us for safety
3 Among patient-applied sensors.
4 Data on file, Abbott Diabetes Care. Comparison based
on publicly available information.
5 The BinaxNOW™ COVID-19 Antigen Self Test is a lateral
flow immunoassay intended for the qualitative detection of
nucleocapsid protein antigen from SARS-CoV-2 from individuals with
or without symptoms or other epidemiological reasons to suspect
COVID-19 infection when tested twice over three days with at least
24 hours (and no more than 48 hours) between tests. This test is
authorized for non-prescription home use with self-collected direct
anterior nasal (nares) swab samples from individuals aged 15 years
or older or adult collected anterior nasal (nares) swab samples
from individuals aged two years or older.
The BinaxNOW™ COVID-19 tests have not been FDA cleared or approved.
They have been authorized by the FDA under an emergency use
authorization. They have been authorized only for the detection of
proteins from SARS-CoV-2, not for any other viruses or pathogens,
and are only authorized for the duration of the declaration that
circumstances exist justifying the authorization of emergency use
of in vitro diagnostics for detection and/or diagnosis of COVID-19
under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act,
21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or
authorization is revoked sooner. For serial testing, the BinaxNOW
COVID-19 Antigen Tests should be performed twice over 3 days, at
least 24 hours (and no more than 48 hours) apart. For symptomatic
use, a single test can be used.
6 Data on file, Abbott Diabetes Care. Data based on the
number of users worldwide for the FreeStyle Libre portfolio
compared to the number of users for other leading personal use,
sensor-based glucose monitoring systems.